

# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	27.4	65.7	(38.9-103.8)	Male	27	17.7	152.8	(100.7-222.4)
Female	11	10.0	109.6	(54.6-196.1)	Female	14	13.7	102.1	(55.8-171.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.1	118.0	(43.1-256.8)	Male	6	5.2	115.6	(42.2-251.5)
Female	3	4.3	nc	(nc-nc)	Female	5	4.2	118.0	(38.0-275.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	11	15.7	70.3	(35.0-125.8)
Female	133	106.5	124.9	(104.5-148.0)	Female	14	13.2	105.9	(57.8-177.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.6	nc	(nc-nc)	Male	12	12.4	96.4	(49.8-168.4)
<b><u>Colon / Rectum</u></b>					Female	4	5.5	nc	(nc-nc)
Male	31	30.5	101.8	(69.1-144.5)	<b><u>Ovary</u></b>				
Female	32	30.8	104.0	(71.1-146.9)	Female	9	9.7	93.0	(42.4-176.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.2	69.3	(22.3-161.6)	Male	13	9.3	140.3	(74.6-239.9)
Female	2	1.9	nc	(nc-nc)	Female	10	9.8	102.0	(48.8-187.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	111	94.8	117.1	(96.3-141.0)
Female	1	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.4	93.8	(34.3-204.3)
Male	18	14.6	122.9	(72.8-194.3)	Female	3	3.9	nc	(nc-nc)
Female	4	8.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.4	179.1	(65.4-389.7)
Male	6	4.0	150.6	(55.0-327.9)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	6	6.7	89.5	(32.7-194.8)
<b><u>Leukemia</u></b>					Female	20	19.0	105.1	(64.2-162.3)
Male	7	10.9	64.5	(25.8-132.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	8.0	125.2	(60.0-230.3)	Female	26	23.9	108.9	(71.1-159.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	9.2	76.1	(30.5-156.9)	Male	374	360.4	103.8	(93.5-114.9)
Female	4	3.0	nc	(nc-nc)	Female	382	363.1	105.2	(94.9-116.3)
<b><u>Lung and Bronchus</u></b>									
Male	43	49.0	87.7	(63.5-118.2)					
Female	48	51.1	93.9	(69.2-124.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Waltham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	54.5	102.7	(77.5-133.3)	Male	32	36.6	87.5	(59.8-123.5)
Female	20	21.0	95.0	(58.0-146.8)	Female	15	31.5	47.7	(26.7-78.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	11.1	99.4	(49.5-177.9)	Male	11	10.4	106.2	(52.9-190.0)
Female	14	9.6	146.3	(79.9-245.4)	Female	4	8.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	27	32.5	83.1	(54.8-121.0)
Female	229	221.0	103.6	(90.6-117.9)	Female	36	28.2	127.5	(89.3-176.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	8.3	132.6	(66.1-237.2)	Male	23	25.2	91.3	(57.8-136.9)
<b><u>Colon / Rectum</u></b>					Female	6	11.6	51.7	(18.9-112.5)
Male	57	60.5	94.3	(71.4-122.1)	<b><u>Ovary</u></b>				
Female	62	64.3	96.4	(73.9-123.6)	Female	19	20.8	91.5	(55.1-142.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	14.5	96.7	(52.8-162.2)	Male	20	18.5	107.9	(65.9-166.7)
Female	2	4.0	nc	(nc-nc)	Female	23	20.6	111.6	(70.7-167.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	5.9	nc	(nc-nc)	Male	162	192.5	84.2	(71.7-98.2)
Female	6	4.9	122.1	(44.6-265.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	12.8	125.1	(71.5-203.1)
Male	35	29.9	116.9	(81.4-162.6)	Female	9	8.1	110.5	(50.4-209.9)
Female	15	17.9	83.8	(46.9-138.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	11.2	98.0	(48.8-175.3)
Male	8	8.0	99.8	(43.0-196.6)	<b><u>Thyroid</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	15	15.2	98.8	(55.3-163.0)
<b><u>Leukemia</u></b>					Female	46	46.1	99.7	(73.0-133.0)
Male	20	22.6	88.4	(54.0-136.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	17.3	92.6	(52.9-150.4)	Female	39	50.2	77.7	(55.2-106.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	18.4	97.6	(57.8-154.3)	Male	692	737.4	93.8	(87.0-101.1)
Female	6	6.3	95.6	(34.9-208.0)	Female	753	773.2	97.4	(90.6-104.6)
<b><u>Lung and Bronchus</u></b>									
Male	102	98.2	103.9	(84.7-126.1)					
Female	113	107.2	105.4	(86.8-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ware

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	11.2	53.7	(19.6-117.0)	Male	4	7.3	nc	(nc-nc)
Female	5	4.0	126.4	(40.7-295.0)	Female	3	5.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	6	6.4	93.7	(34.2-203.9)
Female	30	42.9	70.0	(47.2-99.9)	Female	6	5.3	113.2	(41.3-246.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.2	96.6	(31.1-225.4)
<b><u>Colon / Rectum</u></b>					Female	2	2.2	nc	(nc-nc)
Male	14	12.4	112.9	(61.7-189.5)	<b><u>Ovary</u></b>				
Female	15	12.1	124.2	(69.5-204.8)	Female	5	3.9	126.8	(40.9-295.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	7	3.8	182.8	(73.2-376.7)
Female	2	0.8	nc	(nc-nc)	Female	6	3.9	155.3	(56.7-338.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	30	40.5	74.2	(50.0-105.9)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.6	nc	(nc-nc)
Male	6	6.1	98.6	(36.0-214.6)	Female	0	1.5	nc	(nc-nc)
Female	8	3.4	233.8	(100.7-460.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	8.0	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	3.2	nc	(nc-nc)	Female	7	9.9	71.0	(28.4-146.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	134	149.5	89.6	(75.1-106.2)
Female	1	1.2	nc	(nc-nc)	Female	132	146.0	90.4	(75.7-107.2)
<b><u>Lung and Bronchus</u></b>									
Male	20	20.2	99.2	(60.6-153.2)					
Female	20	20.4	97.8	(59.7-151.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	28.0	150.0	(108.1-202.8)	Male	16	17.7	90.3	(51.6-146.7)
Female	11	9.9	110.6	(55.1-197.9)	Female	15	13.6	110.0	(61.5-181.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.9	102.0	(32.9-238.1)	Male	7	5.3	132.4	(53.0-272.8)
Female	3	4.2	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	22	15.5	141.9	(88.9-214.8)
Female	94	106.6	88.2	(71.3-107.9)	Female	9	13.2	68.1	(31.1-129.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.5	nc	(nc-nc)	Male	17	12.4	136.7	(79.6-218.9)
<b><u>Colon / Rectum</u></b>					Female	6	5.5	109.0	(39.8-237.3)
Male	42	30.1	139.6	(100.6-188.7)	<b><u>Ovary</u></b>				
Female	39	29.8	131.0	(93.1-179.1)	Female	11	9.8	112.7	(56.2-201.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	7.5	146.5	(73.0-262.1)	Male	16	9.5	168.4	(96.2-273.4)
Female	2	1.9	nc	(nc-nc)	Female	11	9.7	113.8	(56.7-203.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	93	101.4	91.7	(74.0-112.3)
Female	3	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.5	108.4	(43.4-223.3)
Male	17	14.8	114.9	(66.9-184.0)	Female	2	3.7	nc	(nc-nc)
Female	11	8.6	128.6	(64.1-230.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.9	nc	(nc-nc)
Male	6	4.2	144.5	(52.8-314.5)	<b><u>Thyroid</u></b>				
Female	4	1.4	nc	(nc-nc)	Male	5	6.4	78.1	(25.2-182.3)
<b><u>Leukemia</u></b>					Female	16	18.6	85.9	(49.1-139.5)
Male	11	10.7	102.9	(51.3-184.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	7.7	181.8	(99.3-305.1)	Female	21	24.8	84.5	(52.3-129.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	9.4	139.0	(73.9-237.7)	Male	446	369.0	120.9	(109.9-132.6)
Female	6	3.0	198.9	(72.6-432.9)	Female	397	362.4	109.5	(99.0-120.9)
<b><u>Lung and Bronchus</u></b>									
Male	82	51.4	159.6	(126.9-198.1)					
Female	83	52.4	158.5	(126.3-196.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.3	112.2	(41.0-244.2)	Male	1	3.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	19	20.1	94.7	(57.0-148.0)	Female	1	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	5.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	7	1.8	379.3	(152.0-781.5)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	13	19.8	65.6	(34.9-112.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.3	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.0	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	6	4.5	133.0	(48.6-289.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	59	73.3	80.5	(61.3-103.9)
Female	0	0.5	nc	(nc-nc)	Female	54	66.1	81.7	(61.4-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	12	9.8	122.2	(63.0-213.4)					
Female	12	8.9	134.6	(69.5-235.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	4.2	118.0	(38.0-275.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	13	14.8	87.9	(46.7-150.3)
Female	0	0.1	nc	(nc-nc)	Female	11	12.2	90.2	(45.0-161.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.0	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	10.9	46.0	(14.8-107.4)
Female	1	0.1	nc	(nc-nc)	Female	8	8.4	95.3	(41.1-187.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.4	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	33.1	126.9	(91.4-171.5)	Male	15	21.5	69.8	(39.0-115.1)
Female	12	13.8	86.9	(44.8-151.8)	Female	19	19.8	96.2	(57.9-150.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.2	162.3	(77.7-298.5)	Male	7	6.2	113.5	(45.5-233.9)
Female	10	5.9	170.0	(81.4-312.7)	Female	6	5.8	103.2	(37.7-224.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	16	18.9	84.5	(48.3-137.3)
Female	146	141.9	102.9	(86.9-121.0)	Female	20	18.2	109.7	(67.0-169.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.3	151.9	(65.4-299.3)	Male	17	14.4	117.9	(68.6-188.7)
<b><u>Colon / Rectum</u></b>					Female	4	7.5	nc	(nc-nc)
Male	41	36.0	113.7	(81.6-154.3)	<b><u>Ovary</u></b>				
Female	38	41.8	90.9	(64.3-124.8)	Female	18	13.2	136.7	(81.0-216.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	8.5	105.7	(48.2-200.7)	Male	14	11.1	126.5	(69.1-212.2)
Female	2	2.6	nc	(nc-nc)	Female	22	13.5	163.4	(102.4-247.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	96	111.0	86.5	(70.0-105.6)
Female	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	7.6	104.6	(45.0-206.1)
Male	22	17.4	126.7	(79.3-191.8)	Female	9	5.3	170.7	(77.9-324.1)
Female	4	11.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.5	109.3	(39.9-237.9)
Male	6	4.7	127.9	(46.7-278.4)	<b><u>Thyroid</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	12	8.3	143.7	(74.2-251.1)
<b><u>Leukemia</u></b>					Female	23	28.2	81.6	(51.7-122.4)
Male	10	13.1	76.3	(36.5-140.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	10.9	100.7	(50.2-180.2)	Female	31	32.2	96.4	(65.5-136.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	10.7	93.8	(44.9-172.5)	Male	431	431.0	100.0	(90.8-109.9)
Female	7	4.1	171.5	(68.7-353.3)	Female	503	496.8	101.3	(92.6-110.5)
<b><u>Lung and Bronchus</u></b>									
Male	60	58.9	101.9	(77.8-131.2)					
Female	71	70.6	100.5	(78.5-126.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wayland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	17.2	46.4	(20.0-91.5)	Male	14	10.7	130.8	(71.5-219.5)
Female	6	5.7	104.8	(38.3-228.1)	Female	13	7.8	166.2	(88.4-284.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	5	3.2	155.0	(50.0-361.7)
Female	5	2.5	203.1	(65.4-473.9)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	9.5	115.9	(57.8-207.4)
Female	75	62.7	119.5	(94.0-149.8)	Female	12	7.6	157.4	(81.3-275.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	3.2	nc	(nc-nc)
Male	13	18.6	69.7	(37.1-119.2)	<b><u>Ovary</u></b>				
Female	10	17.4	57.4	(27.5-105.5)	Female	4	5.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	5	5.8	86.5	(27.9-201.9)
Female	0	1.1	nc	(nc-nc)	Female	5	5.6	89.5	(28.8-208.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	63	59.6	105.7	(81.2-135.2)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.0	nc	(nc-nc)
Male	9	8.9	101.5	(46.3-192.6)	Female	0	2.2	nc	(nc-nc)
Female	5	5.0	100.9	(32.5-235.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	7	3.8	185.6	(74.4-382.5)
<b><u>Leukemia</u></b>					Female	13	10.7	121.4	(64.6-207.6)
Male	8	6.6	122.0	(52.5-240.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.5	nc	(nc-nc)	Female	10	14.5	69.1	(33.1-127.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.7	nc	(nc-nc)	Male	193	222.2	86.9	(75.0-100.0)
Female	3	1.7	nc	(nc-nc)	Female	194	210.5	92.2	(79.7-106.1)
<b><u>Lung and Bronchus</u></b>									
Male	18	30.9	58.3	(34.5-92.1)					
Female	18	29.6	60.7	(36.0-96.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	19.2	166.8	(114.0-235.4)	Male	11	12.2	90.0	(44.9-161.0)
Female	9	7.5	119.7	(54.6-227.3)	Female	5	10.0	50.0	(16.1-116.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	0.6	nc	(nc-nc)	Male	11	10.9	101.3	(50.5-181.3)
Female	83	74.3	111.6	(88.9-138.4)	Female	7	9.7	72.4	(29.0-149.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	4.0	126.5	(40.8-295.3)
Male	27	21.1	128.2	(84.5-186.6)	<b><u>Ovary</u></b>				
Female	27	23.1	116.8	(77.0-170.0)	Female	9	6.9	129.8	(59.2-246.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.0	99.8	(32.2-232.9)	Male	7	6.5	108.1	(43.3-222.7)
Female	1	1.4	nc	(nc-nc)	Female	6	7.5	80.4	(29.4-175.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.5	nc	(nc-nc)	Male	61	66.2	92.1	(70.4-118.3)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.5	nc	(nc-nc)
Male	9	10.1	89.3	(40.8-169.6)	Female	1	3.0	nc	(nc-nc)
Female	9	6.1	148.4	(67.7-281.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.5	nc	(nc-nc)
Male	5	2.7	181.9	(58.6-424.4)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	7	4.6	152.2	(61.0-313.5)
<b><u>Leukemia</u></b>					Female	15	13.4	111.9	(62.6-184.5)
Male	13	7.6	172.0	(91.5-294.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.9	118.2	(47.4-243.6)	Female	20	16.7	119.5	(72.9-184.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	6.3	127.4	(54.8-251.0)	Male	281	250.6	112.1	(99.4-126.1)
Female	7	2.2	324.5	(130.0-668.6)	Female	288	261.3	110.2	(97.9-123.7)
<b><u>Lung and Bronchus</u></b>									
Male	42	34.1	123.3	(88.9-166.7)					
Female	43	36.6	117.3	(84.9-158.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellesley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	28.4	74.0	(45.8-113.1)	Male	28	18.0	155.3	(103.2-224.5)
Female	9	10.8	83.6	(38.1-158.6)	Female	27	15.1	179.3	(118.2-260.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)	Female	8	4.6	175.7	(75.6-346.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	23	16.0	143.5	(91.0-215.4)
Female	129	114.7	112.5	(93.9-133.7)	Female	13	14.3	90.7	(48.2-155.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.8	nc	(nc-nc)	Male	5	12.8	39.0	(12.6-91.0)
<b><u>Colon / Rectum</u></b>					Female	5	5.9	84.2	(27.1-196.5)
Male	17	31.0	54.8	(31.9-87.7)	<b><u>Ovary</u></b>				
Female	22	32.9	66.8	(41.9-101.2)	Female	7	10.6	66.1	(26.5-136.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	7.6	nc	(nc-nc)	Male	8	9.6	83.0	(35.8-163.7)
Female	2	2.1	nc	(nc-nc)	Female	7	10.5	66.4	(26.6-136.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	118	101.3	116.5	(96.4-139.5)
Female	5	2.3	221.1	(71.3-516.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.6	75.8	(24.4-176.9)
Male	8	15.1	52.8	(22.7-104.1)	Female	3	4.2	nc	(nc-nc)
Female	9	9.2	97.9	(44.7-185.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.0	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	12	6.6	180.5	(93.2-315.3)
<b><u>Leukemia</u></b>					Female	22	21.2	104.0	(65.1-157.4)
Male	11	11.3	97.6	(48.7-174.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	8.9	146.8	(78.1-251.1)	Female	16	25.9	61.8	(35.3-100.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	9.5	63.1	(23.0-137.4)	Male	328	374.8	87.5	(78.3-97.5)
Female	2	3.2	nc	(nc-nc)	Female	368	393.5	93.5	(84.2-103.6)
<b><u>Lung and Bronchus</u></b>									
Male	20	51.4	38.9	(23.8-60.1)					
Female	33	55.2	59.8	(41.1-83.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.1	156.2	(67.2-307.7)	Male	3	3.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	5	2.2	222.6	(71.7-519.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	19	18.2	104.5	(62.9-163.2)	Female	2	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	11	5.3	208.0	(103.7-372.3)	<b><u>Ovary</u></b>				
Female	6	5.4	110.9	(40.5-241.4)	Female	3	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	21	18.2	115.6	(71.5-176.7)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.3	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	64	64.9	98.7	(76.0-126.0)
Female	0	0.6	nc	(nc-nc)	Female	66	63.6	103.8	(80.3-132.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	9.3	nc	(nc-nc)					
Female	12	10.0	120.4	(62.1-210.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	4.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	14.8	74.5	(37.1-133.3)
Female	1	0.1	nc	(nc-nc)	Female	9	12.6	71.4	(32.6-135.5)
<b><u>Lung and Bronchus</u></b>									
Male	4	1.9	nc	(nc-nc)					
Female	4	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.0	159.5	(68.7-314.4)	Male	7	3.1	226.8	(90.9-467.4)
Female	2	1.8	nc	(nc-nc)	Female	6	2.4	245.7	(89.7-534.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	17	18.2	93.4	(54.4-149.6)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	2	5.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	5.4	110.9	(40.5-241.4)	Female	1	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	18	16.5	109.3	(64.8-172.8)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	63	63.7	98.9	(76.0-126.6)
Female	0	0.5	nc	(nc-nc)	Female	72	63.5	113.4	(88.8-142.9)
<b><u>Lung and Bronchus</u></b>									
Male	5	8.8	56.5	(18.2-131.9)					
Female	12	9.0	133.3	(68.8-232.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	11.1	143.5	(82.0-233.1)	Male	3	7.1	nc	(nc-nc)
Female	5	3.6	139.5	(45.0-325.5)	Female	0	4.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	6.3	79.4	(25.6-185.2)
Female	37	34.1	108.4	(76.3-149.4)	Female	3	4.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	5	12.4	40.4	(13.0-94.3)	<b><u>Ovary</u></b>				
Female	4	10.8	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	26	37.7	69.0	(45.0-101.1)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.6	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	5.5	162.5	(74.2-308.5)
Male	3	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	7	7.8	90.2	(36.1-185.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	111	144.4	76.9	(63.2-92.6)
Female	2	1.0	nc	(nc-nc)	Female	111	120.7	92.0	(75.7-110.7)
<b><u>Lung and Bronchus</u></b>									
Male	19	19.6	96.7	(58.2-151.1)					
Female	15	17.7	84.9	(47.5-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.4	85.5	(36.8-168.5)	Male	9	5.8	155.2	(70.8-294.7)
Female	2	3.3	nc	(nc-nc)	Female	5	4.3	117.0	(37.7-273.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	117.4	(42.9-255.6)
Female	23	32.9	69.9	(44.3-104.8)	Female	7	4.3	164.6	(65.9-339.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	8	10.0	80.2	(34.5-158.0)	<b><u>Ovary</u></b>				
Female	16	10.1	159.2	(90.9-258.5)	Female	2	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.4	208.6	(67.2-486.7)	Male	2	3.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	32	31.4	102.0	(69.8-144.0)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.1	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	5.6	159.6	(72.8-303.0)
Male	0	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.5	nc	(nc-nc)	Female	7	7.4	94.4	(37.8-194.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	115	119.0	96.7	(79.8-116.0)
Female	0	1.0	nc	(nc-nc)	Female	118	114.8	102.8	(85.1-123.1)
<b><u>Lung and Bronchus</u></b>									
Male	16	16.7	95.7	(54.7-155.4)					
Female	21	16.4	127.7	(79.0-195.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	15	19.6	76.6	(42.8-126.3)	Female	2	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	6	5.5	108.2	(39.5-235.4)	<b><u>Ovary</u></b>				
Female	3	6.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	13	18.2	71.4	(38.0-122.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	5	4.5	111.2	(35.8-259.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	45	66.9	67.3	(49.1-90.0)
Female	0	0.6	nc	(nc-nc)	Female	59	69.2	85.3	(64.9-110.0)
<b><u>Lung and Bronchus</u></b>									
Male	10	9.3	107.2	(51.3-197.2)					
Female	15	10.1	148.1	(82.8-244.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	5	2.3	216.6	(69.8-505.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	0.9	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	21	18.9	111.0	(68.7-169.7)	Female	0	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	4.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	17	18.8	90.4	(52.6-144.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	6	4.4	135.3	(49.4-294.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	49	65.1	75.3	(55.7-99.5)
Female	0	0.5	nc	(nc-nc)	Female	53	59.8	88.6	(66.4-115.9)
<b><u>Lung and Bronchus</u></b>									
Male	3	8.4	nc	(nc-nc)					
Female	7	7.8	89.4	(35.8-184.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	32.1	112.2	(78.6-155.4)	Male	14	20.7	67.8	(37.0-113.7)
Female	10	12.0	83.6	(40.0-153.8)	Female	14	16.5	85.1	(46.5-142.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.9	84.2	(27.1-196.5)	Male	4	6.1	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	12	18.2	65.8	(34.0-115.0)
Female	113	123.4	91.6	(75.5-110.1)	Female	11	15.7	70.1	(35.0-125.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	4.2	282.9	(146.0-494.3)	Male	22	14.5	152.2	(95.3-230.4)
<b><u>Colon / Rectum</u></b>					Female	9	6.5	139.1	(63.5-264.1)
Male	32	35.1	91.2	(62.3-128.7)	<b><u>Ovary</u></b>				
Female	35	36.3	96.4	(67.1-134.0)	Female	7	11.4	61.3	(24.6-126.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.5	152.8	(81.3-261.3)	Male	10	10.9	92.1	(44.1-169.5)
Female	1	2.3	nc	(nc-nc)	Female	8	11.7	68.4	(29.4-134.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	92	113.0	81.4	(65.7-99.9)
Female	1	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.4	80.5	(29.4-175.3)
Male	12	17.1	70.2	(36.3-122.7)	Female	3	4.6	nc	(nc-nc)
Female	8	10.0	80.0	(34.4-157.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.2	117.8	(38.0-274.8)
Male	4	4.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	8	7.8	102.1	(44.0-201.3)
<b><u>Leukemia</u></b>					Female	19	22.7	83.8	(50.4-130.9)
Male	9	12.7	71.1	(32.4-134.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	9.5	63.4	(23.1-137.9)	Female	28	28.1	99.6	(66.2-144.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	10.8	111.3	(57.5-194.5)	Male	379	423.7	89.5	(80.7-98.9)
Female	0	3.5	nc	(nc-nc)	Female	403	427.9	94.2	(85.2-103.8)
<b><u>Lung and Bronchus</u></b>									
Male	54	58.0	93.2	(70.0-121.6)					
Female	76	60.8	125.0	(98.5-156.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	7.7	103.4	(44.5-203.8)	Female	4	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	11	8.2	134.1	(66.9-240.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	30	29.4	101.9	(68.8-145.5)
Female	0	0.2	nc	(nc-nc)	Female	26	25.7	101.3	(66.2-148.4)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.1	nc	(nc-nc)					
Female	3	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	17	13.4	126.6	(73.7-202.8)	Female	3	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.7	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	3.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	14.4	90.1	(47.9-154.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.8	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	46	49.5	93.0	(68.1-124.0)
Female	0	0.4	nc	(nc-nc)	Female	50	43.3	115.6	(85.8-152.4)
<b><u>Lung and Bronchus</u></b>									
Male	2	6.6	nc	(nc-nc)					
Female	6	5.9	102.3	(37.4-222.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	17.7	96.0	(55.9-153.7)	Male	9	11.9	75.8	(34.6-144.0)
Female	7	6.9	101.6	(40.7-209.4)	Female	5	9.9	50.6	(16.3-118.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	6	3.4	175.0	(63.9-380.9)
Female	3	3.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.6	113.6	(58.6-198.4)
Female	75	74.0	101.3	(79.7-127.0)	Female	7	9.2	76.4	(30.6-157.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.7	nc	(nc-nc)	Male	6	8.5	70.2	(25.6-152.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.8	nc	(nc-nc)
Male	17	20.3	83.9	(48.8-134.3)	<b><u>Ovary</u></b>				
Female	31	21.7	143.0	(97.1-202.9)	Female	6	6.8	88.8	(32.4-193.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.8	104.8	(33.8-244.5)	Male	4	6.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	5	6.8	73.3	(23.6-171.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	45	63.1	71.3	(52.0-95.4)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	8	10.0	80.1	(34.5-157.9)	Female	1	2.8	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.7	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	9	4.8	186.9	(85.3-354.8)
<b><u>Leukemia</u></b>					Female	9	14.3	63.0	(28.8-119.7)
Male	9	7.3	122.7	(56.0-232.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.7	106.0	(38.7-230.7)	Female	19	16.2	117.5	(70.7-183.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.2	80.6	(26.0-188.1)	Male	203	240.3	84.5	(73.3-96.9)
Female	1	2.0	nc	(nc-nc)	Female	236	252.5	93.5	(81.9-106.2)
<b><u>Lung and Bronchus</u></b>									
Male	19	31.7	59.9	(36.1-93.6)					
Female	34	34.0	100.1	(69.3-139.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	42.1	95.0	(67.8-129.3)	Male	24	27.4	87.5	(56.0-130.2)
Female	9	15.7	57.2	(26.1-108.5)	Female	18	22.3	80.9	(47.9-127.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	8.1	nc	(nc-nc)	Male	9	8.0	112.3	(51.3-213.2)
Female	7	7.0	100.1	(40.1-206.3)	Female	3	6.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	17	24.4	69.7	(40.6-111.6)
Female	183	167.2	109.5	(94.2-126.5)	Female	17	21.0	81.1	(47.2-129.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.8	138.9	(59.8-273.6)	Male	13	19.6	66.4	(35.3-113.6)
<b><u>Colon / Rectum</u></b>					Female	8	8.7	91.9	(39.6-181.1)
Male	46	46.7	98.4	(72.1-131.3)	<b><u>Ovary</u></b>				
Female	55	48.0	114.6	(86.3-149.2)	Female	17	15.5	109.8	(63.9-175.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	11.3	123.4	(67.4-207.1)	Male	7	14.4	48.6	(19.5-100.2)
Female	3	3.0	nc	(nc-nc)	Female	12	15.4	77.9	(40.2-136.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	3.6	219.9	(94.7-433.3)	Male	128	152.7	83.8	(69.9-99.7)
Female	3	3.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	9.9	141.8	(77.5-237.9)
Male	14	22.9	61.0	(33.3-102.4)	Female	4	6.1	nc	(nc-nc)
Female	13	13.4	97.0	(51.6-165.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	6.0	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	5	10.7	46.7	(15.1-109.0)
<b><u>Leukemia</u></b>					Female	19	31.3	60.7	(36.5-94.8)
Male	16	17.0	94.1	(53.7-152.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	12.7	102.4	(54.5-175.2)	Female	34	38.3	88.8	(61.5-124.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	14.4	76.4	(38.1-136.7)	Male	499	566.4	88.1	(80.5-96.2)
Female	4	4.7	nc	(nc-nc)	Female	546	574.7	95.0	(87.2-103.3)
<b><u>Lung and Bronchus</u></b>									
Male	79	76.1	103.8	(82.2-129.4)					
Female	78	80.5	96.8	(76.6-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	18.9	58.2	(29.0-104.2)	Male	19	13.7	139.1	(83.7-217.2)
Female	2	6.3	nc	(nc-nc)	Female	10	10.8	92.8	(44.4-170.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.3	115.3	(37.2-269.2)	Male	7	3.9	177.3	(71.0-365.3)
Female	5	3.4	148.2	(47.8-345.8)	Female	3	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.6	nc	(nc-nc)	Male	12	12.1	99.6	(51.4-174.0)
Female	89	86.9	102.4	(82.2-126.0)	Female	7	9.3	75.3	(30.2-155.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	14	10.7	130.2	(71.1-218.5)
<b><u>Colon / Rectum</u></b>					Female	3	4.1	nc	(nc-nc)
Male	23	23.1	99.7	(63.2-149.6)	<b><u>Ovary</u></b>				
Female	18	20.0	89.8	(53.2-142.0)	Female	5	7.6	66.0	(21.3-154.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.7	nc	(nc-nc)	Male	7	6.8	102.3	(41.0-210.7)
Female	0	1.2	nc	(nc-nc)	Female	7	6.0	116.4	(46.6-239.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	80	79.2	101.1	(80.1-125.8)
Female	2	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	4.7	147.6	(59.1-304.1)
Male	10	12.3	81.4	(39.0-149.7)	Female	2	2.4	nc	(nc-nc)
Female	2	6.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.8	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	7	6.0	116.3	(46.6-239.6)
<b><u>Leukemia</u></b>					Female	19	17.5	108.5	(65.3-169.4)
Male	11	8.2	134.6	(67.1-240.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	5.5	199.2	(99.3-356.4)	Female	32	19.4	164.7	(112.6-232.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.6	78.7	(28.7-171.2)	Male	286	281.7	101.5	(90.1-114.0)
Female	0	2.1	nc	(nc-nc)	Female	267	271.7	98.3	(86.8-110.8)
<b><u>Lung and Bronchus</u></b>									
Male	32	36.0	89.0	(60.9-125.7)					
Female	29	34.9	83.0	(55.6-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	10	7.6	130.8	(62.6-240.6)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.5	132.9	(63.6-244.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	25	26.3	94.9	(61.4-140.1)
Female	0	0.2	nc	(nc-nc)	Female	14	24.5	57.2	(31.2-95.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.5	nc	(nc-nc)					
Female	0	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.6	105.9	(45.6-208.6)	Male	8	5.2	153.8	(66.2-303.0)
Female	0	2.4	nc	(nc-nc)	Female	8	3.9	206.1	(88.7-406.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.6	153.0	(61.3-315.2)
Female	40	30.5	131.0	(93.6-178.4)	Female	2	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.5	nc	(nc-nc)
Male	11	8.8	125.6	(62.6-224.7)	<b><u>Ovary</u></b>				
Female	6	7.6	78.5	(28.7-170.8)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	26	30.7	84.7	(55.3-124.1)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	6.0	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	6	7.1	84.7	(30.9-184.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	108	108.3	99.7	(81.8-120.4)
Female	0	0.8	nc	(nc-nc)	Female	103	98.6	104.5	(85.3-126.7)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.1	77.9	(38.9-139.5)					
Female	14	12.9	108.5	(59.3-182.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	16.5	90.8	(50.8-149.8)	Male	12	9.8	122.3	(63.1-213.6)
Female	3	5.1	nc	(nc-nc)	Female	11	6.6	165.4	(82.5-296.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.6	227.4	(83.0-495.0)	Male	3	3.0	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	8	8.7	91.7	(39.5-180.7)
Female	60	52.9	113.5	(86.6-146.1)	Female	4	6.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	6	6.6	90.4	(33.0-196.9)
<b><u>Colon / Rectum</u></b>					Female	1	2.7	nc	(nc-nc)
Male	9	17.4	51.8	(23.6-98.3)	<b><u>Ovary</u></b>				
Female	15	15.6	96.2	(53.8-158.7)	Female	3	4.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	4.1	nc	(nc-nc)	Male	5	5.4	92.0	(29.7-214.8)
Female	1	1.0	nc	(nc-nc)	Female	10	5.0	199.3	(95.4-366.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	59	53.6	110.2	(83.9-142.1)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.7	nc	(nc-nc)
Male	3	7.9	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.1	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.7	91.9	(39.6-181.1)
Male	9	6.1	146.7	(67.0-278.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	4.0	225.9	(103.1-428.9)	Female	5	12.0	41.7	(13.4-97.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.1	nc	(nc-nc)	Male	188	204.1	92.1	(79.4-106.3)
Female	1	1.5	nc	(nc-nc)	Female	179	181.0	98.9	(85.0-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	23	29.2	78.9	(50.0-118.4)					
Female	24	25.9	92.6	(59.3-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	22.3	134.2	(90.6-191.7)	Male	16	13.9	114.8	(65.6-186.4)
Female	11	7.4	149.5	(74.5-267.4)	Female	14	9.9	141.3	(77.2-237.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	6	4.2	143.2	(52.3-311.7)
Female	0	3.1	nc	(nc-nc)	Female	5	3.1	159.0	(51.3-371.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	12	12.2	98.2	(50.7-171.5)
Female	68	78.4	86.8	(67.4-110.0)	Female	15	9.7	153.9	(86.1-253.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	2.6	234.5	(85.6-510.4)	Male	7	9.7	71.9	(28.8-148.2)
<b><u>Colon / Rectum</u></b>					Female	6	4.1	148.1	(54.1-322.4)
Male	23	23.8	96.6	(61.2-145.0)	<b><u>Ovary</u></b>				
Female	14	21.8	64.1	(35.0-107.6)	Female	3	7.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	6.0	151.0	(68.9-286.7)	Male	9	7.6	119.2	(54.4-226.2)
Female	1	1.4	nc	(nc-nc)	Female	6	7.2	83.8	(30.6-182.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	91	80.7	112.8	(90.8-138.5)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.1	97.5	(31.4-227.5)
Male	13	11.6	111.7	(59.4-191.1)	Female	3	2.7	nc	(nc-nc)
Female	6	6.3	95.2	(34.8-207.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.1	nc	(nc-nc)
Male	5	3.3	152.6	(49.2-356.1)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	8	4.9	162.1	(69.8-319.4)
<b><u>Leukemia</u></b>					Female	14	13.3	105.0	(57.3-176.2)
Male	8	8.3	96.0	(41.3-189.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.6	nc	(nc-nc)	Female	17	18.4	92.5	(53.9-148.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.3	68.5	(22.1-159.9)	Male	298	291.6	102.2	(90.9-114.5)
Female	1	2.2	nc	(nc-nc)	Female	242	266.5	90.8	(79.7-103.0)
<b><u>Lung and Bronchus</u></b>									
Male	30	40.7	73.7	(49.7-105.2)					
Female	32	39.0	82.1	(56.2-115.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westwood

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	19.6	91.7	(54.3-145.0)	Male	22	11.8	186.3	(116.7-282.0)
Female	2	7.3	nc	(nc-nc)	Female	22	9.0	243.3	(152.4-368.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	5	3.0	165.6	(53.4-386.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	8	10.5	76.1	(32.7-149.9)
Female	95	70.6	134.6	(108.9-164.6)	Female	6	9.2	65.0	(23.7-141.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	7	3.7	187.1	(75.0-385.5)
Male	25	20.9	119.4	(77.2-176.2)	<b><u>Ovary</u></b>				
Female	26	22.4	116.1	(75.8-170.1)	Female	9	6.5	138.8	(63.3-263.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	9	6.5	139.4	(63.6-264.6)
Female	2	1.4	nc	(nc-nc)	Female	3	7.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	66	61.5	107.4	(83.1-136.6)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.4	nc	(nc-nc)
Male	10	9.4	106.1	(50.8-195.1)	Female	1	2.9	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.6	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	7	4.0	177.0	(70.9-364.7)
<b><u>Leukemia</u></b>					Female	20	11.5	173.9	(106.2-268.6)
Male	6	7.5	80.5	(29.4-175.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.6	124.1	(49.7-255.8)	Female	18	15.5	115.9	(68.6-183.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.0	nc	(nc-nc)	Male	249	241.5	103.1	(90.7-116.7)
Female	3	2.1	nc	(nc-nc)	Female	290	247.9	117.0	(103.9-131.2)
<b><u>Lung and Bronchus</u></b>									
Male	24	34.1	70.4	(45.1-104.7)					
Female	38	35.8	106.2	(75.2-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	58.8	95.2	(71.9-123.6)	Male	42	38.2	109.9	(79.2-148.6)
Female	42	23.1	181.5	(130.8-245.4)	Female	41	32.6	125.7	(90.2-170.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	10.9	91.3	(43.7-168.0)	Male	16	11.2	143.2	(81.8-232.6)
Female	13	10.0	129.8	(69.1-222.0)	Female	8	9.9	81.2	(35.0-160.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	45	33.7	133.6	(97.5-178.8)
Female	266	248.5	107.0	(94.6-120.7)	Female	26	30.9	84.2	(55.0-123.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	8.7	92.3	(39.7-181.8)	Male	34	26.8	126.7	(87.7-177.1)
<b><u>Colon / Rectum</u></b>					Female	20	12.8	155.8	(95.1-240.7)
Male	76	65.0	117.0	(92.1-146.4)	<b><u>Ovary</u></b>				
Female	82	70.5	116.4	(92.6-144.5)	Female	29	22.8	127.4	(85.3-183.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	17	15.7	108.6	(63.2-173.9)	Male	21	20.0	105.2	(65.1-160.8)
Female	1	4.4	nc	(nc-nc)	Female	21	22.6	93.0	(57.6-142.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	4.6	130.2	(47.6-283.5)	Male	191	208.0	91.8	(79.3-105.8)
Female	1	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	13.7	94.6	(50.3-161.7)
Male	34	31.8	107.0	(74.1-149.6)	Female	5	8.8	56.6	(18.2-132.0)
Female	29	19.9	145.9	(97.7-209.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	7.8	nc	(nc-nc)
Male	15	8.7	173.2	(96.9-285.7)	<b><u>Thyroid</u></b>				
Female	4	3.1	nc	(nc-nc)	Male	21	14.6	143.6	(88.8-219.5)
<b><u>Leukemia</u></b>					Female	54	46.0	117.4	(88.2-153.2)
Male	21	23.3	90.3	(55.9-138.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	18.4	70.8	(37.6-121.0)	Female	59	56.7	104.0	(79.1-134.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	19	19.8	95.8	(57.6-149.6)	Male	832	780.7	106.6	(99.5-114.1)
Female	7	7.0	100.3	(40.2-206.7)	Female	954	848.2	112.5	(105.4-119.8)
<b><u>Lung and Bronchus</u></b>									
Male	122	106.3	114.7	(95.3-137.0)					
Female	153	119.8	127.7	(108.3-149.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	7.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.7	64.8	(20.9-151.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	19	27.6	68.8	(41.4-107.5)
Female	0	0.2	nc	(nc-nc)	Female	14	24.7	56.7	(31.0-95.1)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.7	nc	(nc-nc)					
Female	1	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whitman

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	12.4	185.8	(117.7-278.7)	Male	8	8.6	92.5	(39.8-182.3)
Female	5	4.5	111.4	(35.9-259.9)	Female	11	7.4	149.6	(74.6-267.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
Female	49	56.1	87.3	(64.6-115.5)	Female	5	6.4	77.9	(25.1-181.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	2.1	283.3	(103.4-616.6)	Male	6	6.4	93.5	(34.1-203.4)
<b><u>Colon / Rectum</u></b>					Female	7	2.7	255.8	(102.5-527.0)
Male	16	14.4	110.9	(63.4-180.2)	<b><u>Ovary</u></b>				
Female	20	14.0	143.3	(87.5-221.4)	Female	1	5.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.5	198.0	(79.3-408.0)	Male	4	4.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	51	48.2	105.8	(78.8-139.1)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.0	nc	(nc-nc)
Male	15	7.5	200.0	(111.8-329.9)	Female	1	1.7	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.2	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	11.5	103.9	(53.6-181.5)
Male	8	5.3	151.0	(65.0-297.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.9	nc	(nc-nc)	Female	16	12.8	125.4	(71.6-203.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	4.6	131.0	(47.8-285.1)	Male	203	176.6	114.9	(99.7-131.9)
Female	0	1.4	nc	(nc-nc)	Female	190	183.1	103.8	(89.6-119.6)
<b><u>Lung and Bronchus</u></b>									
Male	31	22.9	135.4	(92.0-192.2)					
Female	36	24.4	147.3	(103.2-203.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	20.0	74.9	(41.9-123.6)	Male	22	12.2	180.5	(113.1-273.2)
Female	8	7.3	109.3	(47.1-215.3)	Female	9	9.3	97.0	(44.2-184.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.3	153.2	(49.4-357.6)	Male	5	3.7	136.1	(43.9-317.6)
Female	6	2.9	208.1	(76.0-452.9)	Female	1	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.8	111.1	(57.3-194.0)
Female	69	73.1	94.4	(73.4-119.5)	Female	10	9.4	106.7	(51.1-196.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.3	nc	(nc-nc)	Male	5	8.4	59.6	(19.2-139.0)
<b><u>Colon / Rectum</u></b>					Female	0	3.9	nc	(nc-nc)
Male	16	21.4	74.8	(42.7-121.5)	<b><u>Ovary</u></b>				
Female	21	22.2	94.6	(58.5-144.6)	Female	5	6.7	74.4	(24.0-173.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	7	6.7	105.2	(42.1-216.8)
Female	1	1.4	nc	(nc-nc)	Female	15	7.2	208.6	(116.7-344.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	63	66.8	94.4	(72.5-120.7)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.6	nc	(nc-nc)
Male	7	9.9	70.8	(28.4-145.8)	Female	0	2.8	nc	(nc-nc)
Female	6	5.9	100.9	(36.8-219.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.9	92.2	(46.0-165.0)
Male	3	7.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.6	108.0	(39.4-235.0)	Female	12	16.6	72.3	(37.3-126.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	6.4	94.3	(34.4-205.2)	Male	220	252.3	87.2	(76.0-99.5)
Female	2	2.1	nc	(nc-nc)	Female	225	253.5	88.8	(77.5-101.2)
<b><u>Lung and Bronchus</u></b>									
Male	22	35.5	62.1	(38.9-94.0)					
Female	23	36.8	62.5	(39.6-93.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	16	13.3	120.6	(68.9-195.8)	Female	2	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	3.5	172.6	(63.0-375.7)	Female	5	1.2	415.2	(133.8-968.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	12.1	58.1	(23.3-119.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	27	42.5	63.5	(41.8-92.3)
Female	0	0.4	nc	(nc-nc)	Female	53	43.6	121.5	(91.0-158.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.7	nc	(nc-nc)					
Female	5	6.0	83.3	(26.8-194.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.9	73.2	(31.5-144.3)	Male	4	6.2	nc	(nc-nc)
Female	5	4.3	115.9	(37.4-270.6)	Female	1	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.6	125.4	(50.2-258.3)
Female	27	36.6	73.8	(48.6-107.4)	Female	6	5.2	114.3	(41.7-248.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.1	nc	(nc-nc)
Male	6	11.0	54.4	(19.9-118.4)	<b><u>Ovary</u></b>				
Female	10	12.8	78.1	(37.4-143.6)	Female	3	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	52	33.3	156.1	(116.6-204.7)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	5	4.7	105.4	(34.0-246.0)	Female	1	1.7	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.7	nc	(nc-nc)
Male	4	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	3.2	nc	(nc-nc)	Female	4	8.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.1	nc	(nc-nc)	Male	118	129.7	91.0	(75.3-109.0)
Female	3	1.2	nc	(nc-nc)	Female	101	136.4	74.0	(60.3-90.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	18.7	58.9	(29.4-105.4)					
Female	18	20.6	87.4	(51.8-138.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	22.7	127.9	(85.7-183.7)	Male	9	15.1	59.4	(27.1-112.9)
Female	12	8.1	148.7	(76.7-259.7)	Female	16	12.0	133.1	(76.0-216.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	8	3.5	231.1	(99.5-455.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	8	13.4	59.7	(25.7-117.6)
Female	109	93.0	117.2	(96.2-141.4)	Female	16	11.0	145.2	(83.0-235.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.3	nc	(nc-nc)	Male	11	10.9	100.6	(50.1-179.9)
<b><u>Colon / Rectum</u></b>					Female	7	4.6	151.3	(60.6-311.8)
Male	23	25.8	89.2	(56.5-133.8)	<b><u>Ovary</u></b>				
Female	23	25.1	91.7	(58.1-137.6)	Female	7	8.3	84.0	(33.6-173.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.2	nc	(nc-nc)	Male	6	7.8	77.0	(28.1-167.6)
Female	0	1.5	nc	(nc-nc)	Female	10	7.8	127.6	(61.1-234.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	70	82.4	84.9	(66.2-107.3)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.4	111.1	(40.6-241.9)
Male	17	12.8	132.4	(77.1-212.0)	Female	5	3.1	159.2	(51.3-371.6)
Female	9	7.2	124.5	(56.8-236.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	3.1	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	8	6.1	132.1	(56.9-260.4)
<b><u>Leukemia</u></b>					Female	13	17.9	72.6	(38.6-124.2)
Male	18	9.2	194.8	(115.4-307.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	6.7	nc	(nc-nc)	Female	24	20.6	116.4	(74.6-173.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	8.0	nc	(nc-nc)	Male	299	308.7	96.9	(86.2-108.5)
Female	4	2.5	nc	(nc-nc)	Female	349	309.0	112.9	(101.4-125.4)
<b><u>Lung and Bronchus</u></b>									
Male	46	41.3	111.5	(81.6-148.7)					
Female	51	42.1	121.1	(90.1-159.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	9.7	144.7	(79.0-242.7)	Male	1	6.6	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	5	1.9	260.9	(84.1-608.9)
Female	0	1.6	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	31	39.3	78.8	(53.6-111.9)	Female	4	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.4	nc	(nc-nc)	Male	6	4.9	123.5	(45.1-268.8)
<b><u>Colon / Rectum</u></b>					Female	2	1.9	nc	(nc-nc)
Male	8	11.2	71.7	(30.9-141.3)	<b><u>Ovary</u></b>				
Female	16	10.1	157.9	(90.2-256.4)	Female	4	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	5	3.4	148.3	(47.8-346.1)
Female	2	0.6	nc	(nc-nc)	Female	7	3.1	222.2	(89.0-457.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	33	36.5	90.5	(62.3-127.1)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	5	3.0	164.3	(52.9-383.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.9	88.8	(35.6-182.9)
Male	4	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	9	8.8	102.4	(46.7-194.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	124	135.2	91.7	(76.3-109.3)
Female	0	1.0	nc	(nc-nc)	Female	136	129.6	104.9	(88.0-124.1)
<b><u>Lung and Bronchus</u></b>									
Male	15	17.8	84.1	(47.0-138.7)					
Female	24	17.7	135.6	(86.9-201.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	25.1	91.7	(58.1-137.6)	Male	19	15.8	120.3	(72.4-187.8)
Female	5	9.7	51.4	(16.6-119.9)	Female	16	12.7	125.8	(71.9-204.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	10	4.0	248.6	(119.0-457.2)	Female	6	4.1	148.0	(54.0-322.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.0	114.3	(65.3-185.6)
Female	99	98.9	100.1	(81.4-121.9)	Female	11	12.6	87.6	(43.7-156.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	5	11.0	45.5	(14.7-106.2)
<b><u>Colon / Rectum</u></b>					Female	5	5.1	97.2	(31.3-226.8)
Male	31	27.4	113.3	(76.9-160.8)	<b><u>Ovary</u></b>				
Female	23	29.9	76.9	(48.7-115.4)	Female	8	9.0	88.5	(38.1-174.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.5	76.7	(24.7-178.9)	Male	5	8.4	59.4	(19.1-138.7)
Female	1	1.8	nc	(nc-nc)	Female	8	9.6	83.1	(35.8-163.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	98	85.3	114.9	(93.2-140.0)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.8	nc	(nc-nc)
Male	7	13.1	53.6	(21.5-110.4)	Female	5	3.8	130.9	(42.2-305.6)
Female	8	8.0	100.3	(43.2-197.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.5	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	1	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	17.1	128.7	(80.6-194.9)
Male	12	9.8	122.2	(63.1-213.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.7	78.0	(28.5-169.7)	Female	19	21.9	86.6	(52.1-135.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	8.2	73.4	(26.8-159.8)	Male	304	324.1	93.8	(83.6-105.0)
Female	2	2.8	nc	(nc-nc)	Female	330	341.3	96.7	(86.5-107.7)
<b><u>Lung and Bronchus</u></b>									
Male	34	44.8	75.9	(52.6-106.1)					
Female	43	48.0	89.7	(64.9-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	5	1.4	367.2	(118.3-856.9)	<b><u>Ovary</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	17.1	58.4	(28.0-107.4)
Female	0	0.1	nc	(nc-nc)	Female	12	13.3	90.5	(46.7-158.1)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.2	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	21.6	106.4	(67.4-159.6)	Male	24	13.9	173.1	(110.9-257.6)
Female	8	7.9	101.8	(43.8-200.6)	Female	20	11.0	182.6	(111.5-282.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	7	3.4	208.4	(83.5-429.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	5	12.2	41.1	(13.2-95.9)
Female	91	84.7	107.5	(86.5-132.0)	Female	10	10.5	95.5	(45.7-175.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.9	nc	(nc-nc)	Male	11	9.7	112.8	(56.3-201.9)
<b><u>Colon / Rectum</u></b>					Female	1	4.4	nc	(nc-nc)
Male	27	23.6	114.2	(75.2-166.1)	<b><u>Ovary</u></b>				
Female	22	23.8	92.6	(58.0-140.2)	Female	12	7.7	155.1	(80.1-271.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.8	104.1	(38.0-226.6)	Male	11	7.3	149.7	(74.6-267.9)
Female	0	1.5	nc	(nc-nc)	Female	8	7.6	104.7	(45.1-206.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	70	77.3	90.5	(70.6-114.4)
Female	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.0	nc	(nc-nc)
Male	22	11.5	190.6	(119.4-288.6)	Female	2	3.0	nc	(nc-nc)
Female	14	6.8	206.8	(113.0-347.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.6	nc	(nc-nc)
Male	5	3.2	157.4	(50.7-367.2)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	8	5.2	154.1	(66.4-303.6)
<b><u>Leukemia</u></b>					Female	16	15.2	105.0	(60.0-170.6)
Male	8	8.4	95.8	(41.2-188.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.1	81.9	(26.4-191.1)	Female	22	19.5	112.6	(70.5-170.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	7.2	110.8	(47.7-218.4)	Male	320	285.6	112.0	(100.1-125.0)
Female	3	2.4	nc	(nc-nc)	Female	322	287.8	111.9	(100.0-124.8)
<b><u>Lung and Bronchus</u></b>									
Male	58	39.1	148.3	(112.6-191.7)					
Female	46	41.1	111.9	(81.9-149.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	55	43.1	127.6	(96.1-166.1)	Male	33	27.6	119.6	(82.3-168.0)
Female	22	17.1	128.3	(80.4-194.3)	Female	21	23.0	91.2	(56.5-139.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.8	76.6	(28.0-166.7)	Male	7	8.0	87.2	(34.9-179.7)
Female	10	7.0	142.0	(68.0-261.1)	Female	7	7.2	97.8	(39.2-201.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	29	24.3	119.2	(79.8-171.2)
Female	190	171.6	110.7	(95.5-127.6)	Female	27	22.2	121.8	(80.2-177.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	5.9	118.2	(47.4-243.5)	Male	21	18.7	112.5	(69.6-172.0)
<b><u>Colon / Rectum</u></b>					Female	11	9.0	121.6	(60.6-217.5)
Male	62	46.9	132.1	(101.3-169.4)	<b><u>Ovary</u></b>				
Female	51	52.0	98.1	(73.0-129.0)	Female	20	15.9	126.1	(77.0-194.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	11.1	108.6	(56.0-189.7)	Male	17	14.4	118.4	(68.9-189.5)
Female	1	3.3	nc	(nc-nc)	Female	20	16.8	119.3	(72.8-184.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	124	143.3	86.5	(72.0-103.2)
Female	2	2.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.9	100.7	(48.2-185.2)
Male	26	22.4	116.2	(75.9-170.2)	Female	8	6.6	121.4	(52.3-239.3)
Female	17	14.1	120.8	(70.3-193.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	6.0	116.5	(46.7-240.0)
Male	1	6.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	11	10.4	106.0	(52.8-189.7)
<b><u>Leukemia</u></b>					Female	34	31.3	108.5	(75.1-151.7)
Male	20	16.9	118.4	(72.3-182.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	13.4	126.9	(73.9-203.1)	Female	41	38.5	106.6	(76.5-144.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	13.9	100.7	(55.0-169.0)	Male	618	556.3	111.1	(102.5-120.2)
Female	1	5.0	nc	(nc-nc)	Female	670	601.2	111.4	(103.2-120.2)
<b><u>Lung and Bronchus</u></b>									
Male	97	76.8	126.2	(102.4-154.0)					
Female	83	86.5	95.9	(76.4-118.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worcester

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	176	156.5	112.4	(96.4-130.3)	Male	61	104.0	58.7	(44.9-75.4)
Female	68	61.5	110.6	(85.9-140.2)	Female	53	90.9	58.3	(43.7-76.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	28	32.3	86.8	(57.6-125.4)	Male	28	29.6	94.4	(62.7-136.5)
Female	24	28.6	84.0	(53.8-124.9)	Female	25	25.9	96.5	(62.4-142.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	103	93.0	110.8	(90.4-134.4)
Female	559	647.6	86.3	(79.3-93.8)	Female	84	82.3	102.0	(81.4-126.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	34	24.1	141.3	(97.9-197.5)	Male	73	72.3	101.0	(79.1-126.9)
<b><u>Colon / Rectum</u></b>					Female	38	33.8	112.3	(79.5-154.1)
Male	154	175.3	87.8	(74.5-102.9)	<b><u>Ovary</u></b>				
Female	186	190.2	97.8	(84.2-112.9)	Female	63	60.5	104.2	(80.1-133.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	56	41.1	136.2	(102.9-176.8)	Male	48	53.0	90.5	(66.7-120.0)
Female	12	11.7	102.8	(53.1-179.6)	Female	64	60.4	105.9	(81.6-135.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	14	16.0	87.7	(47.9-147.2)	Male	522	540.4	96.6	(88.5-105.3)
Female	15	14.0	107.3	(60.0-177.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	37	36.8	100.7	(70.9-138.8)
Male	91	85.4	106.5	(85.8-130.8)	Female	32	24.1	132.5	(90.6-187.1)
Female	58	52.3	110.9	(84.2-143.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	19	29.0	65.5	(39.4-102.3)
Male	18	22.7	79.2	(46.9-125.1)	<b><u>Thyroid</u></b>				
Female	11	7.8	141.3	(70.4-252.8)	Male	44	42.5	103.6	(75.3-139.1)
<b><u>Leukemia</u></b>					Female	111	133.2	83.3	(68.5-100.3)
Male	61	66.0	92.4	(70.7-118.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	53	51.6	102.6	(76.9-134.3)	Female	159	144.6	110.0	(93.5-128.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	83	52.9	157.0	(125.0-194.6)	Male	2105	2098.1	100.3	(96.1-104.7)
Female	22	18.2	120.9	(75.7-183.0)	Female	2195	2257.4	97.2	(93.2-101.4)
<b><u>Lung and Bronchus</u></b>									
Male	333	278.5	119.6	(107.1-133.1)					
Female	357	309.1	115.5	(103.8-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	3	6.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	6.8	87.7	(32.0-190.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	27	23.2	116.2	(76.5-169.0)
Female	0	0.2	nc	(nc-nc)	Female	17	20.4	83.4	(48.6-133.6)
<b><u>Lung and Bronchus</u></b>									
Male	5	3.1	161.2	(52.0-376.3)					
Female	0	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.1	98.7	(49.2-176.7)	Male	5	7.6	65.8	(21.2-153.6)
Female	3	4.3	nc	(nc-nc)	Female	11	6.1	179.0	(89.2-320.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.7	148.6	(71.1-273.3)
Female	53	48.1	110.2	(82.6-144.2)	Female	1	5.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	6	2.4	245.7	(89.7-534.7)
Male	20	13.0	153.6	(93.8-237.2)	<b><u>Ovary</u></b>				
Female	9	13.7	65.7	(30.0-124.7)	Female	3	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.2	190.2	(69.5-414.0)	Male	4	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	56	43.0	130.3	(98.4-169.2)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.7	nc	(nc-nc)
Male	4	6.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	8.8	57.0	(18.4-132.9)
Male	3	4.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.5	nc	(nc-nc)	Female	4	10.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	174	156.5	111.2	(95.3-129.0)
Female	3	1.3	nc	(nc-nc)	Female	145	161.1	90.0	(75.9-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	22	20.4	107.8	(67.5-163.2)					
Female	15	21.7	69.0	(38.6-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	47.3	110.0	(82.2-144.3)	Male	38	26.4	143.9	(101.9-197.6)
Female	27	17.7	152.3	(100.3-221.6)	Female	45	19.6	230.1	(167.8-307.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	6.4	nc	(nc-nc)	Male	10	8.1	123.4	(59.1-227.0)
Female	8	6.0	132.9	(57.2-261.8)	Female	8	7.2	110.6	(47.6-218.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	28	23.3	120.0	(79.7-173.4)
Female	172	152.6	112.7	(96.5-130.9)	Female	23	21.5	107.1	(67.9-160.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.3	nc	(nc-nc)	Male	22	16.3	135.1	(84.7-204.6)
<b><u>Colon / Rectum</u></b>					Female	11	8.5	128.8	(64.2-230.5)
Male	43	47.0	91.5	(66.2-123.2)	<b><u>Ovary</u></b>				
Female	45	51.5	87.4	(63.7-117.0)	Female	9	14.4	62.5	(28.5-118.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	19	11.0	172.1	(103.5-268.7)	Male	19	15.0	126.3	(76.0-197.2)
Female	5	3.4	148.7	(47.9-347.0)	Female	13	17.4	74.5	(39.6-127.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.1	234.5	(75.6-547.2)	Male	166	138.6	119.8	(102.3-139.5)
Female	3	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	10.2	58.8	(21.5-128.0)
Male	14	20.1	69.7	(38.1-116.9)	Female	5	6.6	75.7	(24.4-176.7)
Female	11	13.2	83.1	(41.4-148.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.8	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	12	7.5	159.7	(82.4-279.0)
<b><u>Leukemia</u></b>					Female	12	21.3	56.3	(29.0-98.3)
Male	29	16.5	176.2	(118.0-253.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	12.5	135.8	(79.1-217.4)	Female	31	35.4	87.5	(59.5-124.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	12.8	109.3	(59.7-183.5)	Male	621	545.6	113.8	(105.0-123.1)
Female	8	4.9	162.4	(69.9-319.9)	Female	611	559.3	109.2	(100.7-118.2)
<b><u>Lung and Bronchus</u></b>									
Male	92	81.5	112.9	(91.0-138.4)					
Female	98	88.2	111.1	(90.2-135.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;